SCHEMBL1745260

SCHEMBL1745260

O=C(Nc1ccc2nc(C3CC(N4CCCCC4)C3)sc2c1)N1CCOCC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 6/20 0.56
▸ RAB9A P51151 4/20 0.56
▸ HSD17B10 Q99714 2/20 0.56
▸ KDM4E B2RXH2 7/20 0.50
▸ ALDH1A1 P00352 6/20 0.50
▸ TSHR P16473 2/20 0.48
▸ KMT2A Q03164 4/20 0.47
▸ MAPT P10636 3/20 0.47
▸ MEN1 O00255 3/20 0.47
▸ GAA P10253 2/20 0.47
▸ HPGD P15428 2/20 0.47
▸ USP2 O75604 1/20 0.47
▸ CASP1 P29466 1/20 0.47
▸ CASP7 P55210 1/20 0.47
▸ LMNA P02545 1/20 0.46
▸ TP53 P04637 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ THRB P10828 2/20 0.45
▸ PTPN7 P35236 1/20 0.45
▸ CACNA1B Q00975 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1745541 1.00 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
SCHEMBL1745263 1.00 SMN1; SMN2 (0.56) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
SCHEMBL9994957 0.86 MAPT (0.44) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
SCHEMBL9994638 0.86 MAPT (0.44) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
Cyclopentane SCHEMBL9994808 0.85 RAB9A (0.52) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
SCHEMBL9994885 0.85 RAB9A (0.52) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
Cyclohexane SCHEMBL9995190 0.85 RAB9A (0.52) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
SCHEMBL9994799 0.85 RAB9A (0.52) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
Cyclohexane SCHEMBL9994983 0.85 RAB9A (0.52) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1
SCHEMBL9995183 0.85 RAB9A (0.52) SMN1; SMN2RAB9AHSD17B10KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2386556-B1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands ABBVIE INC (US) 2013-10-23 — — EP claimed
EP-1926729-B1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LAB (US) 2011-12-21 — — EP claimed
EP-2386556-A1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands Abbott Laboratories (US) 2011-11-16 — — EP claimed
US-20110254413-A1 CASING OF ELECTRONIC DEVICE AND MANUFACTURING METHOD THEREOF ASUSTEK COMPUTER INC. (TW) 2011-10-20 — — US claimed
US-7576110-B2 Benzothiazole cyclobutyl amine derivatives ABBOTT LABORATORIES (US) 2009-08-18 — — US claimed
EP-1926729-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LABORATORIES (US) 2008-06-04 — — EP claimed
WO-2007038074-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LABORATORIES (US) 2007-04-05 — — WO claimed
US-20070066588-A1 Benzothiazole cyclobutyl amine derivatives ABBVIE INC. 2007-03-22 — — US claimed
US-8592467-B2 Benzothiazole cyclobutyl amine derivatives ABBVIE INC. (US) 2013-11-26 — — US disclosed
EP-2386556-B1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands ABBVIE INC (US) 2013-10-23 — — EP disclosed
EP-1926729-B1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LAB (US) 2011-12-21 — — EP disclosed
EP-2386556-A1 Benzothiazole cyclobutyl amine derivatives and their use as histamine-3 receptors ligands Abbott Laboratories (US) 2011-11-16 — — EP disclosed
US-20110254413-A1 CASING OF ELECTRONIC DEVICE AND MANUFACTURING METHOD THEREOF ASUSTEK COMPUTER INC. (TW) 2011-10-20 — — US disclosed
US-20090326222-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES ABBOTT LABORATORIES (US) 2009-12-31 — — US disclosed
US-7576110-B2 Benzothiazole cyclobutyl amine derivatives ABBOTT LABORATORIES (US) 2009-08-18 — — US disclosed
EP-1926729-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LABORATORIES (US) 2008-06-04 — — EP disclosed
WO-2007038074-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES AND THEIR USE AS HISTAMINE-3 RECEPTORS LIGANDS ABBOTT LABORATORIES (US) 2007-04-05 — — WO disclosed
US-20070066588-A1 Benzothiazole cyclobutyl amine derivatives ABBVIE INC. 2007-03-22 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326222-A1 BENZOTHIAZOLE CYCLOBUTYL AMINE DERIVATIVES HRH2, HRH4, HRH1 SMN1; SMN2 3835/4885RAB9A 2543/4885HSD17B10 2068/4885
US-20070066588-A1 Benzothiazole cyclobutyl amine derivatives HRH2, HRH4, HRH1 SMN1; SMN2 3835/4885RAB9A 2543/4885HSD17B10 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback